Banks launch €1.5 billion debt package investor soundings for Lone Star's Lonza spin-off unit
Arranging banks have begun investor soundings on a €1.5 billion debt financing package to support Lone Star's acquisition of a unit being divested by Swiss life sciences group Lonza, according to reporting flagged by Private Equity Wire. The debt package — the form of which has not been disclosed in the available sources — is being marketed to institutional investors as part of a broader leveraged buyout (LBO) financing, where the acquisition is funded using a mix of equity from the PE sponsor and debt raised against the target's cash flows. Investor soundings — where banks informally test institutional appetite for a deal before committing to a formal syndication — are a standard pre-marketing step in the European leveraged finance market. Their launch signals that the arranging banks have sufficient confidence in the transaction's credit profile to begin building a book, and that Lone Star is moving toward deal close. The life sciences sector has remained active for PE deal-making in 2026 despite broader market uncertainty: contract development and manufacturing organisations (CDMOs) — which Lonza's divested unit is reported to involve — generate predictable, long-term contract revenues that lend themselves well to leveraged capital structures. The €1.5 billion quantum sits at the upper end of mid-market European leveraged finance and will test appetite in a market where private credit BDCs (business development companies — listed vehicles that lend to mid-market companies) are trading at their deepest discounts to NAV (net asset value) in over five years, according to LSEG data.
Why this matters
The launch of investor soundings on a €1.5 billion European leveraged debt package is a live signal that PE sponsors and their banks still believe the syndicated loan market can clear large life-sciences LBO financings despite elevated spreads and BDC stress. The 'why now' trigger is a combination of PE portfolio pressure — sponsors need to deploy dry powder and execute portfolio exits — and life sciences sector resilience, which has kept CDMO assets in demand. The transaction generates significant work across leveraged finance (facility agreement negotiation, covenant package, intercreditor deed), acquisition finance (security package over Lonza unit assets, likely including IP and contract rights), and regulatory (Swiss and potentially UK pharmaceutical regulatory consents on change of control). Firms with strong European leveraged finance and life sciences capabilities are best positioned for both the arranging-bank and sponsor mandates.
On the Ground
A trainee on the lender-side team would manage the conditions precedent (CP) checklist — tracking delivery of each document required before the facility can be drawn, including legal opinions from local counsel in relevant jurisdictions, landlord waivers over key manufacturing facilities, and security document execution confirmations. They would also assist with reviewing facility agreement schedules and coordinating execution logistics across the signing syndicate.
Interview prep
Soundbite
Life sciences LBO debt at €1.5 billion tests whether European syndicated markets can absorb large sponsor-backed deals as BDC stress widens pricing.
Question you might get
“What key risks would a lender syndicate focus on when underwriting a €1.5 billion leveraged finance package for a pharmaceutical CDMO, and how would those risks be reflected in the covenant package?”
Full answer
Banks are running investor soundings on a €1.5 billion debt package for Lone Star's acquisition of a Lonza business unit, marking one of the larger European leveraged finance transactions to hit the market this week. This matters because it tests institutional appetite for syndicated leveraged debt at a moment when private credit BDCs — the alternative lending channel — are trading at their deepest NAV discounts in five years, suggesting the public leveraged loan and high-yield bond markets may need to absorb more volume than expected. The life sciences sector is the key enabler: CDMO businesses generate long-term contracted revenues that underpin the credit case even in a volatile rate environment. The broader trend is that PE sponsors are using sector selectivity — focusing on defensive, contracted-revenue businesses — to keep deal financing executable. This suggests leveraged finance practices will remain active through H2 2026 so long as sponsors maintain sector discipline.
My notes
saved